Clinical Trials
83 trialsNCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT02297438 2026-05-14
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT04746924 2026-05-12
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
BeOne Medicines
Phase 3 Terminated
NCT05104866 2026-05-05
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT01298323 2026-04-17
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
Phase 3 Completed
NCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01933932 2025-11-19
SELECT-1
AstraZeneca
Phase 3 Active not recruiting
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT03257267 2025-04-08
Study of Cemiplimab in Adults With Cervical Cancer
Regeneron Pharmaceuticals
Phase 3 Completed
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT04685135 2025-01-22
KRYSTAL-12
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT00365105 2024-09-20
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT05223673 2024-08-20
COLSTAR
Servier
Phase 3 Terminated
NCT01231347 2024-07-16
GAMMA
NantCell, Inc.
Phase 3 Completed
NCT02049905 2024-06-13
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Phase 3 Completed
NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04887506 2024-01-16
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Phase 3 Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00113763 2022-11-07
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00377156 2022-09-16
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01372774 2022-09-16
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT03042611 2022-07-08
ANGEL
Elevar Therapeutics
Phase 3 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT00116142 2022-01-11
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT03654729 2021-12-17
POLAR-M
Egetis Therapeutics
Phase 3 Terminated
NCT00134056 2021-10-27
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT00369785 2021-10-20
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Phase 3 Completed